Osiris to Present Clinical and Scientific Studies at Symposium on Advanced Wound Care (SAWC)
October 06 2016 - 5:00PM
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading regenerative
medicine company focused on developing and marketing products to
treat conditions in wound care, orthopaedics and sports medicine,
will present advanced clinical and scientific research at the
Symposium on Advanced Wound Care (SAWC) Fall Conference.
On Friday, October 7, Dr. Matthew Regulski, DPM, will be
speaking on “The Use of Viable Placental Membranes in Complex
Wounds” at the Breakfast Symposium from 7:30 a.m. to 9:00 a.m.
On Saturday, October 8, Dr. Dane Wukich, MD, and Dr. Jodi
Walters, DPM, will be presenting a CME lecture (supported by
Osiris) on “Clinical and Scientific Advances in the Use of
Cryopreserved Placental Membranes in Complex Wounds” from 11:20
a.m. to 12:20 p.m.
- “A prospective, multicentre, open-label, single-arm clinical
trial for the treatment of chronic complex diabetic foot wounds
with exposed tendon and/or bone: positive clinical outcomes of a
viable cryopreserved human placental membrane” (Int Wound J. 2016;
doi:10.111/iwj.12649 [E-pub ahead of print]) recently reported that
96.3% of patients achieved complete granulation for a complex wound
in a mean of 6.8 weeks, 59.3% of which demonstrated 100%
re-epithelialization in a mean of 9.1 weeks. Enrolled patient
characteristics included serious health conditions typically
excluded from clinical research such as hypertension, end stage
renal disease with hemodialysis, previous partial foot amputation
and peripheral arterial disease. This is the first post-market
study of its kind in the wound care space.
Osiris will be presenting 8 abstracts on cryopreserved placental
tissue technology.
Scientific and Clinical Abstracts:
- “Viable Cryopreserved Placental Allografts for the Treatment of
Post-Surgical Amputation Wounds in High-Risk Patients” (Abstract #
CS-069)
- “Use of a Viable Cryopreserved Umbilical Tissue for Surgical
Tendon Repair” (Abstract # CS-105)
- “Management of Wounds of Various Etiologies Using a Viable
Cryopreserved Placental Membrane” (Abstract # CS-108)
- “Viable Cryopreserved Human Placental Membrane Induces
Granulation Over Exposed Bone, Tendon and Joint Surfaces of the
Hand to Support Skin Autograft Survival” (Abstract # CS-117)
- “Single Layer Viable Placental Allografts Show a Superior
Dynamic Response Over Multi-layer Non-viable Allografts to an In
Vitro Wound Microenvironment” (Abstract # LB-020)
- “Up-regulation of Anti-inflammatory and Anti-microbial Activity
in Human Cryopreserved Viable Placental Membrane in the Presence of
Bacterial Antigens” (Abstract # LB-028)
- “Antimicrobial Peptides in Human Cryopreserved Viable Placental
Membrane Inhibit Bacterial Growth” (Abstract # LB-039)
- “Human Viable Cryopreserved Amniotic Membrane (hCVAM) Induces
Angiogenesis in a Nestin-driven Green Fluorescent Protein (ND-GFP)
Transgenic Mouse Model” (Abstract # LB-047)
Osiris Therapeutics will also be exhibiting at the Symposium on
Advanced Wound Care meeting at booth 327. The event runs from
October 7 through October 9, 2016 at the Caesars Palace in Las
Vegas, Nevada.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a
world leader in researching, developing and marketing regenerative
medicine products that improve health and lives of patients and
lower overall healthcare costs. Having developed the world's first
approved stem cell drug, the company continues to advance its
research and development in biotechnology by focusing on innovation
in regenerative medicine - including bioengineering, stem cell
research and viable tissue based products. Osiris has achieved
commercial success with products in orthopaedics, sports medicine
and wound care, including BIO4®, Cartiform®, Grafix® , TruSkinTM
and StravixTM. Osiris, Grafix, and Cartiform are registered
trademarks of Osiris Therapeutics, Inc.; TruSkin and Stravix are
trademarks of Osiris Therapeutics, Inc. BIO4® is a trademark of
Howmedica Osteonics Corp. More information can be found on the
company's website, www.Osiris.com. (OSIR-G).
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements include statements about our
expectations, beliefs, plans, objectives, intentions, assumptions
and other statements that are not historical facts. Words or
phrases such as "anticipate," "believe," "continue," "ongoing,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project" or similar words or phrases, or the negatives
of those words or phrases, may identify forward-looking statements,
but the absence of these words does not necessarily mean that a
statement is not forward-looking. Examples of forward-looking
statements may include, without limitation, statements regarding
any of the following: the outcome of the NASDAQ listing
qualification deficiency process, including the ability of the
Company to successfully maintain its NASDAQ listing; the outcome of
the restatements, including the materiality, significance, nature,
subject matter, timing or quantitative effects of the Company's
restated financial statements; the timing of the transition to a
new independent registered public accounting firm; the completion
of the audit of the Company's 2015 financial statements; and the
timing of the filing of the Company's 2015 Form 10-K, Q1 2016 Form
10-Q and Q2 2016 Form 10-Q. Forward-looking statements are subject
to known and unknown risks and uncertainties and are based on
potentially inaccurate assumptions that could cause actual results
to differ materially from those expected or implied by the
forward-looking statements. Our actual results could differ
materially from those anticipated in forward-looking statements for
many reasons, including the factors described in the section
entitled "Risk Factors" in our Annual Report on Form 10-K and other
Periodic Reports filed on Form 10-Q, with
the SEC. Accordingly, you
should not unduly rely on these forward-looking statements. We
undertake no obligation to publicly revise any forward-looking
statement to reflect circumstances or events after the date of this
press release or to reflect the occurrence of unanticipated
events.
For additional information, please contact:
Diane Savoie
Osiris Therapeutics, Inc.
(443) 545-1834
OsirisPR@Osiris.com
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Apr 2023 to Apr 2024